Is immunoprophylaxis with palivizumab justified for respiratory syncytial virus?

被引：1
|
作者：
Paul, Siba P. [1 ]
Ball, Georgina M. [2 ]
机构：
[1] Torbay Hosp, Dept Paediat, Torquay TQ2 7AA, England
[2] Peninsula Coll Med & Dent, Plymouth, Devon, England
来源：
BRITISH JOURNAL OF HOSPITAL MEDICINE | 2017年 / 78卷 / 08期
关键词：
D O I：
10.12968/hmed.2017.78.8.476
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：476 / 476
页数：1
相关论文
共 50 条
  • [41] Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis
    Oliveira, Danielle B. L.
    Iwane, Marika K.
    Prill, Mila M.
    Weinberg, Geoffrey A.
    Williams, John V.
    Griffin, Marie R.
    Szilagyi, Peter G.
    Edwards, Kathryn M.
    Staat, Mary A.
    Hall, Caroline B.
    Durigon, Edison L.
    Erdman, Dean D.
    JOURNAL OF CLINICAL VIROLOGY, 2015, 65 : 26 - 31
  • [42] Palivizumab for prophylaxis of respiratory syncytial virus infections in preterm neonates
    Gortner, Ludwig
    KLINISCHE PADIATRIE, 2017, 229 (05): : 259 - 260
  • [43] Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing
    Simoes, Eric A. F.
    Groothuis, Jessil R.
    Carbonell-Estrany, Xavier
    Reger, Christian H. L.
    Mitchell, Ian
    Fredrick, Linda M.
    Kimpen, Jan L. L.
    JOURNAL OF PEDIATRICS, 2007, 151 (01): : 34 - 42
  • [44] Palivizumab prophylaxis, respiratory syncytial virus and subsequent development of asthma
    Igde, Mahir
    Kabasakal, Hilal
    Ozturk, Onur
    Karatekin, Guner
    Aygun, Canan
    MINERVA PEDIATRICA, 2018, 70 (03) : 252 - 259
  • [45] The Loss of Respiratory Syncytial Virus Seasonality and the Effects on Palivizumab Administration
    Tan, Darren
    Goff, Zoy
    MacDonald, Bradley
    Blyth, Christopher C.
    Foley, David A.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2022, 41 (09) : E407 - E408
  • [46] A review of cost-effectiveness of palivizumab for respiratory syncytial virus
    Hussman, Julia M.
    Li, Abby
    Paes, Bosco
    Lanctot, Krista L.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2012, 12 (05) : 553 - 567
  • [47] Palivizumab prophylaxis for respiratory syncytial virus in Canada:: utilization and outcomes
    Oh, PI
    Lanctôt, KL
    Yoon, A
    Lee, DSC
    Paes, BA
    Simmons, BS
    Parison, D
    Manzi, P
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2002, 21 (06) : 512 - 518
  • [48] The Prevention of Respiratory Syncytial Virus Infection in Children: Focus on Palivizumab
    Speer, Michael E.
    Good, Amy B.
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 459 - 469
  • [49] Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab
    Mahadevia, Parthiv J.
    Malinoski, Frank J.
    ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2007, 161 (05): : 519 - 520
  • [50] Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab
    Reeve, Carole A.
    Whitehall, John S.
    Buettner, Petra G.
    Norton, Robert
    Reeve, David M.
    Francis, Fleur
    JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2006, 42 (05) : 253 - 258
12345